COST-EFFECTIVENESS OF OFATUMUMAB COMPARED WITH OTHER DISEASE-MODIFYING THERAPIES FOR THE TREATMENT OF RELAPSING MULTIPLE SCLEROSIS IN GREECE

被引：0
|
作者：
Petropoulos, A. [1 ]
Cooney, P. [2 ]
Patidar, M. [3 ]
Gudala, K. [3 ]
Tiwari, S. [4 ]
Brennan, R. [2 ]
Kapsogeorgiou, K. [1 ]
Cheilas, G. [1 ]
Banhazi, J. [5 ]
机构：
[1] Novartis Hellas SACI, Athens A1, Greece
[2] Novartis Ireland Ltd, Dublin, Ireland
[3] Novartis Healthcare Private Ltd, Hyderabad, India
[4] Novartis Healthcare Private Ltd, Hyderabad, Andhra Pradesh, India
[5] Novartis Pharma AG, Basel, BS, Switzerland
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE143
引用
收藏
页码：S80 / S81
页数：2
相关论文
共 50 条
  • [1] The cost-effectiveness of disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis
    Bozkaya, Duygu
    Livingston, Terrie
    Migliaccio-Walle, Kristen
    Odom, Tanner
    JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (03) : 297 - 302
  • [2] Cost-effectiveness of injectable disease-modifying therapies for the treatment of relapsing forms of multiple sclerosis in Spain
    Carole Dembek
    Leigh Ann White
    Jayson Quach
    Andrea Szkurhan
    Nazia Rashid
    M. R. Blasco
    The European Journal of Health Economics, 2014, 15 : 353 - 362
  • [3] Cost-effectiveness of injectable disease-modifying therapies for the treatment of relapsing forms of multiple sclerosis in Spain
    Dembek, Carole
    White, Leigh Ann
    Quach, Jayson
    Szkurhan, Andrea
    Rashid, Nazia
    Blasco, M. R.
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2014, 15 (04): : 353 - 362
  • [4] Cost-Effectiveness of Disease-Modifying Therapies in Multiple Sclerosis
    Ali Manouchehrinia
    Cris S. Constantinescu
    Current Neurology and Neuroscience Reports, 2012, 12 : 592 - 600
  • [5] Cost-Effectiveness of Disease-Modifying Therapies in Multiple Sclerosis
    Manouchehrinia, Ali
    Constantinescu, Cris S.
    CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2012, 12 (05) : 592 - 600
  • [6] Cost-Effectiveness of Injectable Disease-Modifying Therapies in the Treatment of Multiple Sclerosis
    Quach, Jayson
    Dembek, Carole
    Szkurhan, Andrea
    Rashid, Nazia
    Blasco, M. R.
    NEUROLOGY, 2011, 76 (09) : A474 - A474
  • [7] Cost-effectiveness of ofatumumab in comparison with other disease modifying therapies and best supportive care for the treatment of relapsing-remitting multiple sclerosis in Canada
    Mouallif, S.
    Thomas, K.
    Adlard, N.
    Cooney, P.
    Blanchette, F.
    Patel, B.
    Baharnoori, M.
    Bhan, V.
    Clift, F.
    Grima, D.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 311 - 311
  • [8] THE COST-EFFECTIVENESS OF DISEASE MODIFYING THERAPIES FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS
    Bozkaya, D.
    Livingston, T. P.
    Migliaccio-Walle, K.
    Mehta, S.
    Odom, T.
    VALUE IN HEALTH, 2015, 18 (03) : S283 - S283
  • [9] Comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis
    Samjoo, Imtiaz A.
    Worthington, Evelyn
    Drudge, Christopher
    Zhao, Melody
    Cameron, Chris
    Haering, Dieter A.
    Stoneman, Dee
    Klotz, Luisa
    Adlard, Nicholas
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2020, 9 (18) : 1255 - 1274
  • [10] COST-EFFECTIVENESS OF OFATUMUMAB IN TREATMENT OF RELAPSING MULTIPLE SCLEROSIS IN TURKEY
    Tatar, M.
    Yarci, B.
    Akdemir, A. C.
    Olmez, C.
    Tinaz, E.
    Turanli, M.
    VALUE IN HEALTH, 2023, 26 (12) : S148 - S148
12345